Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker XENE
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | Christopher Kenney Officer | XENE Xenon Pharmaceuticals Inc. | 7,068 | $437.7K | 10b5-1 | Aug 28, 2026 | Form 4 ↗ 3 days later · 7,068 shares | Form 144 ↗ |
| Aug 13, 2026 | Steven Gannon Director | XENE Xenon Pharmaceuticals Inc. | 10,000 | $640.6K | — | Aug 11, 2026 | Form 4 ↗ same day · 10,000 shares | Form 144 ↗ |
| Jun 5, 2026 | Gillian Cannon Director | XENE Xenon Pharmaceuticals Inc. | 1,190 | $63.1K | 10b5-1 | Jun 5, 2026 | Form 4 ↗ 3 days later · 1,190 shares | Form 144 ↗ |
| Jun 5, 2026 | Gary Patou Director | XENE Xenon Pharmaceuticals Inc. | 1,322 | $70.1K | 10b5-1 | Jun 5, 2026 | Form 4 ↗ 3 days later · 1,322 shares | Form 144 ↗ |
| Mar 13, 2026 | Christopher John Kenney Officer | XENE Xenon Pharmaceuticals Inc. | 1,410 | $77.9K | 10b5-1 | Mar 13, 2026 | Form 4 ↗ same day · 1,410 shares | Form 144 ↗ |
| Mar 13, 2026 | Andrea Difabio Officer | XENE Xenon Pharmaceuticals Inc. | 1,342 | $74.1K | 10b5-1 | Mar 13, 2026 | Form 4 ↗ same day · 1,342 shares | Form 144 ↗ |
| Mar 13, 2026 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 7,308 | $403.6K | 10b5-1 | Mar 13, 2026 | Form 4 ↗ same day · 7,308 shares | Form 144 ↗ |
| Mar 10, 2026 | Andrea Difabio Officer | XENE Xenon Pharmaceuticals Inc. | 2,607 | $156.7K | 10b5-1 | Mar 10, 2026 | Form 4 ↗ 1 day later · 2,607 shares | Form 144 ↗ |
| Mar 10, 2026 | Christopher John Kenney Officer | XENE Xenon Pharmaceuticals Inc. | 2,771 | $166.6K | 10b5-1 | Mar 10, 2026 | Form 4 ↗ 1 day later · 2,771 shares | Form 144 ↗ |
| Mar 10, 2026 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 11,269 | $677.4K | 10b5-1 | Mar 10, 2026 | Form 4 ↗ 1 day later · 281,269 shares | Form 144 ↗ |
| Mar 9, 2026 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 270,000 | $16.3M | 10b5-1 | Mar 9, 2026 | Form 4 ↗ 2 days later · 281,269 shares | Form 144 ↗ |
| Jan 2, 2026 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 40,000 | $1.8M | 10b5-1 | Jan 2, 2026 | Form 4 ↗ same day · 40,000 shares | Form 144 ↗ |
| Dec 8, 2025 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 10,830 | $495.2K | 10b5-1 | Dec 8, 2025 | Form 4 ↗ 1 day later · 25,205 shares | Form 144 ↗ |
| Dec 5, 2025 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 14,375 | $647.4K | 10b5-1 | Dec 5, 2025 | Form 4 ↗ 4 days later · 25,205 shares | Form 144 ↗ |
| Dec 1, 2025 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 97 | $4,366 | 10b5-1 | Nov 28, 2025 | Form 4 ↗ 8 days later · 25,205 shares | Form 144 ↗ |
| Oct 1, 2025 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 25,000 | $1.0M | 10b5-1 | Oct 1, 2025 | Form 4 ↗ same day · 25,000 shares | Form 144 ↗ |
| Sep 19, 2025 | Sherry Aulin Former officer | XENE Xenon Pharmaceuticals Inc. | 2,548 | $94.5K | — | Sep 19, 2025 | — | Form 144 ↗ |
| Jan 27, 2025 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 16,315 | $660.8K | 10b5-1 | Jan 27, 2025 | Form 4 ↗ same day · 38,783 shares | Form 144 ↗ |
| Jan 24, 2025 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 22,468 | $903.3K | 10b5-1 | Jan 24, 2025 | Form 4 ↗ 3 days later · 55,000 shares | Form 144 ↗ |
| Jan 23, 2025 | Ian Mortimer Officer, Director | XENE Xenon Pharmaceuticals Inc. | 16,217 | $649.9K | 10b5-1 | Jan 23, 2025 | Form 4 ↗ 4 days later · 55,000 shares | Form 144 ↗ |
| Dec 18, 2024 | Sherry Aulin Officer | XENE Xenon Pharmaceuticals Inc. | 18,709 | $770.9K | — | Dec 18, 2024 | Form 4 ↗ 1 day later · 18,709 shares | Form 144 ↗ |
| Nov 22, 2024 | Gary Patou Director | XENE Xenon Pharmaceuticals Inc. | 4,891 | $200.9K | — | Nov 22, 2024 | Form 4 ↗ same day · 4,891 shares | Form 144 ↗ |
| Jul 12, 2024 | Simon Pimstone Former Director | XENE Xenon Pharmaceuticals Inc. | 70,000 | $3.0M | — | Jul 12, 2024 | — | Form 144 ↗ |
| Jun 12, 2024 | Robin Sherrington Officer (non-Section 16) | XENE Xenon Pharmaceuticals Inc. | 60,000 | $2.3M | — | Jun 12, 2024 | — | Form 144 ↗ |
| Jun 5, 2024 | Simon Pimstone Former Director | XENE Xenon Pharmaceuticals Inc. | 110,000 | $4.2M | — | Jun 5, 2024 | — | Form 144 ↗ |
| Mar 8, 2024 | Elizabeth Garofalo Director | XENE Xenon Pharmaceuticals Inc. | 2,092 | $95.6K | — | Mar 8, 2024 | — | Form 144 ↗ |
| Mar 7, 2024 | Robin Sherrington Officer | XENE Xenon Pharmaceuticals Inc. | 7,137 | $330.3K | — | Mar 7, 2024 | — | Form 144 ↗ |
| Mar 7, 2024 | Steven Gannon Director | XENE Xenon Pharmaceuticals Inc. | 13,000 | $600.3K | — | Mar 7, 2024 | — | Form 144 ↗ |
| Dec 14, 2023 | Gary Patou Director | XENE Xenon Pharmaceuticals Inc. | 7,598 | $307.1K | — | Dec 14, 2023 | — | Form 144 ↗ |
| Dec 13, 2023 | Gary Patou Director | XENE Xenon Pharmaceuticals Inc. | 11,380 | $454.1K | — | Dec 13, 2023 | — | Form 144 ↗ |
| Aug 24, 2023 | Dawn Svoronos Director | XENE Xenon Pharmaceuticals Inc. | 25,000 | $967.5K | — | Aug 24, 2023 | — | Form 144 ↗ |
| Jun 1, 2023 | Simon Pimstone Director | XENE Xenon Pharmaceuticals Inc. | 31,713 | $1.2M | — | Jun 1, 2023 | — | Form 144 ↗ |
| May 31, 2023 | Simon Pimstone Director | XENE Xenon Pharmaceuticals Inc. | 50,526 | $1.9M | — | May 31, 2023 | — | Form 144 ↗ |
| May 31, 2023 | Simon Pimstone Director | XENE Xenon Pharmaceuticals Inc. | 12,000 | $462.4K | — | May 31, 2023 | — | Form 144 ↗ |
| May 30, 2023 | Simon Pimstone Director | XENE Xenon Pharmaceuticals Inc. | 37,006 | $1.4M | — | May 30, 2023 | — | Form 144 ↗ |
| May 24, 2023 | Ian Mortimer Director, Officer | XENE Xenon Pharmaceuticals Inc. | 31,655 | $1.3M | — | May 24, 2023 | — | Form 144 ↗ |
36 items, most recent first (up to 50). Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 9:53 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances